Evidence map›Paper›PMID 39893473›Full record

SynthesisBMC infectious diseases2025

Critical assessment of uncertainty in economic evaluations on influenza vaccines for the elderly population in Spain.

Raúl Ortiz-de-Lejarazu Leonardo, Javier Díez Domingo, Ángel Gil de Miguel, Federico Martinón Torres, Esther Redondo Margüello, Juan Luis López-Belmonte Claver, Paloma I Palomo-Jiménez, J Manel Farré Avellà, José María Abellán Perpiñán

Abstract readSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Raúl Ortiz-de-Lejarazu LeonardoCentro Nacional de Gripe de Valladolid, GISRS (Global Influenza Surveillance and Response System), Valladolid, Spain. lejarazu@gmail.com.
Javier Díez DomingoFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
Ángel Gil de MiguelPreventive and Public Health Department, Rey Juan Carlos University, Madrid, Spain.
Federico Martinón TorresTranslational Paediatrics and Infectious Diseases Section, Paediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.
Esther Redondo MargüelloInternational Healthcare Centre of Ayuntamiento de Madrid, Madrid, 28006, Spain.
Juan Luis López-Belmonte ClaverSanofi, Market Access, Madrid, Spain.
Paloma I Palomo-JiménezSanofi, Market Access, Madrid, Spain.
J Manel Farré AvellàSanofi, Medical Affairs, Barcelona, Spain.
José María Abellán PerpiñánApplied Economics Department, Economics & Enterprise Faculty, University of Murcia, Murcia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfluenza is a seasonal infection with a huge impact on morbidity and mortality in older adults, for whom vaccination is recommended. New influenza vaccines for this population have been introduced in Spain in the past 5 years, and a number of cost-effectiveness analyses (CEA) have been published to aid healthcare decision-making. The objective of this study was to assess possible sources of uncertainty in the CEAs of influenza vaccines for the older adults in Spain.

methodsA systematic review was performed to identify Spanish CEAs published since 2016. Potential sources of structural, methodologic and parametric uncertainty in CEA results were systematically analysed using the TRansparent Uncertainty ASsessmenT (TRUST) Tool, quality assessment checklists, and the WHO guidance on economic evaluations of influenza vaccine strategies. The primary sources of efficacy/effectiveness were analysed in depth to ascertain whether they could support the conclusions of the respective CEAs.

resultsSeven CEAs were included. Overall, they were designed and performed in accordance with the applicable guidelines; however, some critical sources of uncertainty were detected, mainly: (1) the choice and use of efficacy/effectiveness data (real-world single season studies, meta-analyses including studies with high risk of bias and/or high heterogeneity with biased interpretation); (2) use of fewer than 5 seasons to estimate influenza burden; (3) generalized use of influenza-like illness data to estimate effectiveness and burden, among others.

conclusionsSeemingly well-designed studies may conceal important sources of uncertainty that affect the results. This must be taken into account when interpreting results to support decision-making.

Indexed as

Cost-Benefit AnalysisInfluenza, HumanInfluenza VaccinesAgedAged, 80 and overHumansSpainUncertaintyVaccinationInfluenza VaccinesCost-effectiveness analysisInfluenza vaccinationQuality of evidenceTRUST ToolUncertainty analysis

Identifiers

PMID39893473
PMCPMC11786407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.